


**INFORMATION DISCLOSURE  
CITATION**

ATTY. DOCKET NO.

249-426

SERIAL NO.

10/575,261

APPLICANT

IIDA ET AL.

(Use several sheets if necessary)

FILING DATE

April 10, 2006

GROUP

~~1653~~ 1644
**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

**FOREIGN PATENT DOCUMENTS**

DOCUMENT		DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 00/12113	03/2000	WIPO				

**OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)**

	Majeau et al, "Mechanism of Lymphocyte Function-Associated Molecule 3-Ig Fusion Proteins Inhibition of T Cell Responses", Journal of Immunology, 1994, 152:2753-2767
	da Silva et al, "Alefacept, an Immunomodulatory Recombinant LFA-3/IgG1 Fusion Protein, Induces CD16 Signaling and CD2/CD16-Dependent Apoptosis of CD2 <sup>+</sup> Cells <sup>1</sup> ", The Journal of Immunology, 2002, 168:4462-4471
	Cooper et al, "Alefacept selectively promotes NK cell-mediated deletion of CD45R0 <sup>+</sup> human T cells", Eur. J. Immunol. 2003, 33:666-675
	Sorbera et al, "Alefacept - Antipsoriatic", Drugs of the Future 2001, 26(6):527-532
	EP 1 109 570 A0, June 27, 2001 (equivalent to above-listed WO 00/12113 (published on March 9, 2000))
	Supplementary European Search Report dated November 19, 2007, issued in connection with EP 04 77 3776

\*Examiner /Chun Dahle/ (08/07/2009) Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)